Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shanghai - Delayed Quote CNY

Well Lead Medical Co., Ltd. (603309.SS)

11.75
+0.03
+(0.26%)
At close: 3:00:02 PM GMT+8
Loading Chart for 603309.SS
  • Previous Close 11.72
  • Open 11.83
  • Bid 11.74 x --
  • Ask 11.75 x --
  • Day's Range 11.62 - 11.89
  • 52 Week Range 9.45 - 14.67
  • Volume 3,956,920
  • Avg. Volume 3,597,395
  • Market Cap (intraday) 3.441B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 15.06
  • EPS (TTM) 0.78
  • Earnings Date --
  • Forward Dividend & Yield 0.50 (4.27%)
  • Ex-Dividend Date May 23, 2024
  • 1y Target Est --

Well Lead Medical Co., Ltd. engages in the development, production, and sale of medical devices in anaesthesia, urology, endourology, respiratory, pain management, and hemodialysis areas worldwide. It manufactures and sells urology products, including Foley catheter, Nelaton catheters, urine collection products, and accessories; endourology products, such as the ClearPetra family system, ureterorenoscope, guide wires, ureteral stent, and stone retrieval basket; anesthesia products, comprising endotracheal tubes, intubation accessories, laryngeal masks, endobronchial tubes, tracheostomy tubes, anesthesia breathing circuits and accessories, and nasopharyngeal and oropharyngeal airway products; respiratory products, including oxygen and aerosol therapy products, and capnography mask and cannula products; drainage/suction/gastroenterology products, such as drainage systems, Yankauer handles, suction catheters, and stomach and feeding tubes; hemodialysis blood tubing set; home care products, including male external catheter and Convicath intermittent catheter; and ambulatory infusion pump for pain management. The company was founded in 1998 and is headquartered in Guangzhou, China.

www.wellead.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 603309.SS

View More

Performance Overview: 603309.SS

Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

603309.SS
1.92%
SSE Composite Index (000001.SS)
0.27%

1-Year Return

603309.SS
3.82%
SSE Composite Index (000001.SS)
6.19%

3-Year Return

603309.SS
0.96%
SSE Composite Index (000001.SS)
11.36%

5-Year Return

603309.SS
1.99%
SSE Composite Index (000001.SS)
16.41%

Compare To: 603309.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 603309.SS

View More

Valuation Measures

Annual
As of 5/7/2025
  • Market Cap

    3.44B

  • Enterprise Value

    3.48B

  • Trailing P/E

    15.06

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.22

  • Price/Book (mrq)

    1.77

  • Enterprise Value/Revenue

    2.25

  • Enterprise Value/EBITDA

    12.31

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.73%

  • Return on Assets (ttm)

    6.17%

  • Return on Equity (ttm)

    12.27%

  • Revenue (ttm)

    1.55B

  • Net Income Avi to Common (ttm)

    228.06M

  • Diluted EPS (ttm)

    0.78

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    475.91M

  • Total Debt/Equity (mrq)

    26.01%

  • Levered Free Cash Flow (ttm)

    -20.26M

Research Analysis: 603309.SS

View More

Company Insights: 603309.SS

Research Reports: 603309.SS

View More

People Also Watch